^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    glufosfamide (D 19575)

    i
    Other names: D 19575, β-D-Glc-IPM, beta-D-Glc-IPM
    Associations

    News

    Trials
    Company:
    Eleison Pharma
    Drug class:
    Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    1year
    Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P3, N=480, Recruiting, Eleison Pharmaceuticals LLC. | Trial completion date: Mar 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • 5-fluorouracil • glufosfamide (D 19575)
    over3years
    An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart. (PubMed, J Egypt Natl Canc Inst)
    The current study reported for the first time cytotoxicity activity of glufosfamide in HepG2 cells in vitro. The obtained results confirmed the higher oncolytic activity of glufosfamide than its aglycone ifosfamide. The generated data warrants further elucidations by in vivo study.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
    |
    BCL2 expression • CASP3 elevation
    |
    Zymafos (palifosfamide) • glufosfamide (D 19575)